Mirgezumab for use in method of treating Crohn's disease
Through the induction and maintenance dosing regimen of megilizumab, the shortcomings of existing CD treatment methods in terms of therapeutic efficacy and tolerance were solved, and the endoscopic response rate and clinical response rate in CD patients were significantly improved, quality of life was improved, and good performance in safety and tolerance were performed.
Patent Information
- Application Number
- CN202411949868.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-04-22
- Filing Date
- 2020-04-15
- Publication Date
- 2025-03-28
AI Technical Summary
Existing treatments for Crohn's disease (CD) still have shortcomings in therapeutic efficacy, safety and tolerance, especially in patients with moderate to severe CD, where a more effective treatment regimen is needed.
The dosing regimen of megilizumab, including administration to the patient at least one inducible and maintenance dose of megilizumab, inducible doses comprising about 200 mg to about 1200 mg, maintenance doses comprising about 100 mg to about 600 mg, administration by intravenous infusion or subcutaneous injection.
Through the use of megilizumab, endoscopic response and clinical response rates in patients with moderate to severe CD have been significantly improved, quality of life in patients with moderate to severe CD, and performed well in terms of safety and tolerance.